Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.
|Videos|December 17, 2017
Recurrent Infection: An Unmet Medical Need in the Realm of C. difficile
Author(s)Contagion® Editorial Staff
Dr. Richard Vickers explains how recurrent infection is an unmet medical need when it comes to C. difficile.
Advertisement
Dr. Richard Vickers, chief scientific officer of R&D at Summit Therapeutics, explains how recurrent infection is an unmet medical need when it comes to C. difficile.
Interview Transcript (modified slightly for readability):
“The consequences of collateral damage caused by antibiotics on the gut microbiome is recurrent Clostridium difficile infection (CDI). And recurrent infection is the key unmet medical need in C. diff. Each time a patient has an episode of CDI, his/her risk of having future episodes increases. Typically, after an initial episode, 25-30% of patients will have a recurrence, but by the time they get to their second or third episode, that risk can rise to 65%.
Patients fall into these terribly debilitating cycles: infection, cure, infection, cure, infection, cure. Recurrences typically occur only a couple of weeks after an initial episode, so it really does become quite an intense experience for the patients. Each recurrent episode, as I said, is associated with increased risk of further recurrences, increased mortality, and increased morbidity.
It’s very difficult for physicians to manage; we don’t have good treatment options available. Recurrent CDI has a huge impact not only on patient welfare but also on the health care system as a whole, between the costs associated with increased length of stay and readmission rates, it has a huge impact.”
Advertisement
Related to this article
In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.
Projected disease burden from declining childhood vaccine coverage shows increases in vaccine-preventable diseases. Benjamin Lopman, PhD, provides insights on how VaxImpactMap works and the potential long-term disease consequences of decreased immunization rates.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
Advertisement
Advertisement
Trending on Contagion Live
1
Cefiderocol-Xeruborbactam Active Against Carbapenem-Resistant Bacteria
2
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
3
Ensitrelvir PEP Eases Symptom Severity in COVID-19 Breakthrough Cases
4
Early Antibiotic Stop in Neutropenic Fever Did Not Raise Severe Events
5